SCH-58261

SCH-58261
Clinical data
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine;
CAS Number	160098-96-4 ;
PubChem CID	176408;
IUPHAR/BPS	403;
ChemSpider	153647 ;
UNII	4309023MAH;
ChEMBL	ChEMBL17127 ;
CompTox Dashboard (EPA)	DTXSID80166799 ;
Chemical and physical data
Formula	C18H15N7O
Molar mass	345.366 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccccc1CCN1N=CC2=C1N=C(N)N3C2=NC(C4=CC=CO4)=N3;
	InChI InChI=1S/C18H15N7O/c19-18-22-16-13(11-20-24(16)9-8-12-5-2-1-3-6-12)17-21-15(23-25(17)18)14-7-4-10-26-14/h1-7,10-11H,8-9H2,(H2,19,22) ; Key:UTLPKQYUXOEJIL-UHFFFAOYSA-N ;
	(what is this?) (verify)

SCH-58261 is a drug which acts as a potent and selective antagonist for the adenosine receptor A_2A, with more than 50x selectivity for A_2A over other adenosine receptors.^[1] It has been used to investigate the mechanism of action of caffeine, which is a mixed A₁ / A_2A antagonist, and has shown that the A_2A receptor is primarily responsible for the stimulant and ergogenic effects of caffeine,^[2] but blockade of both A₁ and A_2A receptors is required to accurately replicate caffeine's effects in animals.^[3]^[4]^[5]^[6] SCH-58261 has also shown antidepressant,^[7] nootropic and neuroprotective effects in a variety of animal models,^[8]^[9]^[10]^[11]^[12]^[13] and has been investigated as a possible treatment for Parkinson's disease.^[14]^[15]